Compare BELFB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFB | PHVS |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | BELFB | PHVS |
|---|---|---|
| Price | $169.21 | $27.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $153.75 | $39.44 |
| AVG Volume (30 Days) | 133.3K | ★ 469.3K |
| Earning Date | 02-17-2026 | 11-12-2025 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | ★ 19.52 | N/A |
| EPS | ★ 5.17 | N/A |
| Revenue | ★ $649,376,000.00 | N/A |
| Revenue This Year | $28.52 | N/A |
| Revenue Next Year | $6.49 | N/A |
| P/E Ratio | $32.82 | ★ N/A |
| Revenue Growth | ★ 23.70 | N/A |
| 52 Week Low | $58.00 | $11.51 |
| 52 Week High | $179.41 | $29.80 |
| Indicator | BELFB | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 60.63 |
| Support Level | $171.59 | $25.27 |
| Resistance Level | $177.04 | $26.09 |
| Average True Range (ATR) | 5.94 | 1.27 |
| MACD | -0.71 | 0.16 |
| Stochastic Oscillator | 42.69 | 94.72 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.